Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
Review ArticlePractice

Medication management and pharmacokinetic changes after bariatric surgery

Sabrina Lorico and Blaine Colton
Canadian Family Physician June 2020, 66 (6) 409-416;
Sabrina Lorico
Pharmacist completing a pharmacy residency at the Red Deer Regional Hospital Centre within Alberta Health Services.
PharmD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Blaine Colton
Medication Safety Pharmacist at Alberta Health Services and was previously a pharmacist at the Central Alberta Bariatric Clinic.
BScPharm
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: blaine.colton@ahs.ca
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Abstract

Objective To identify expected pharmacokinetic changes and provide practical recommendations for the medication management of chronic disease states after bariatric surgery.

Sources of information MEDLINE, EMBASE, PubMed, Scopus, and the Cochrane Library were searched. The search was limited to studies in human adults. Search terms included obesity, obese, bariatric surgery, gastric bypass, gastrectomy, gastric band, RYGB, roux-en-y, gastrointestinal absorption, medication absorption, drug absorption, bioavailability, dose adjust, drug monitoring, medication adjust, drug change, medication change, medication management, and medication dosing. Reference lists of original studies and reviews were also hand searched. Included studies were entered into PubMed and articles under the “Similar articles” heading were also reviewed. Only studies relevant to bariatric surgery types currently available in Canada (ie, Roux-en-Y gastric bypass, sleeve gastrectomy, or gastric banding) were included.

Main message Pharmacokinetic changes anticipated after bariatric surgery vary by surgery type. There are several guiding principles that might be applied to medication management regimens after bariatric surgery. Practice tips are also presented for medication management of specific chronic disease states.

Conclusion Changes to long-term medication regimens after bariatric surgery should be anticipated and managed in an appropriate and timely manner. The provided clinical practice recommendations might be used in conjunction with a patient’s clinical picture to adjust chronic medication regimens in an appropriate and evidence-based manner after bariatric surgery.

Obesity is a progressive chronic health condition affecting more than 1 in 4 adult Canadians.1 Patients who are obese are at an increased risk of many other serious health conditions including type 2 diabetes, hypertension, cardiovascular disease, arthritis, and various types of cancer.2 Bariatric surgery structurally modifies the gastrointestinal tract to reduce caloric consumption or absorption. The number of bariatric surgeries performed annually in Canada has more than tripled since 2009.3

In addition to restricting caloric absorption, bariatric surgeries also have the unintended potential to restrict absorption of other enteral products, including vitamins, minerals, and medications. After surgery, patients typically experience rapid weight loss and might require adjustments to long-term medication regimens owing to changing medication distribution patterns and the effects of weight loss on chronic disease states.

Bariatric surgeries are classified as having restrictive or malabsorptive properties. Restrictive surgeries reduce the volume of food that can be consumed at one time, leading to reduced total caloric intake. Malabsorptive procedures create a diversion around substantial portions of the digestive tract causing reduced absorption of consumed products. Bariatric surgeries currently offered in Canada include Roux-en-Y gastric bypass (RYGB), in which a small functional pouch at the top of the stomach is isolated from the rest of the stomach and directly connected to the jejunum, allowing food to bypass most of the stomach and the entire duodenum; sleeve gastrectomy, in which approximately 80% of the stomach is removed, leaving a smaller sleevelike stomach; and gastric banding, in which an obstructive band is placed around the proximal stomach, physically restricting the rate at which food can pass into the stomach. Roux-en-Y gastric bypass has both restrictive and malabsorptive properties, while sleeve gastrectomy and gastric banding are primarily restrictive procedures.

Unfortunately, the current literature offers very few clear recommendations regarding specific medication management strategies in patients after bariatric surgery. The objective of this review is to identify expected pharmacokinetic changes and provide practical recommendations for the medication management of chronic disease states after bariatric surgery based on the current available evidence.

Case description

A 40-year-old woman is 2 weeks removed from an RYGB procedure and presents to a family medicine clinic with an elevated blood pressure of 158/96 mm Hg. All other vital signs are within normal limits. Her medical history is relevant for class III obesity and stage 1 hypertension, which had previously been well controlled with 10 mg of oral ramipril daily and 60 mg of oral extended-release nifedipine daily. The patient indicates she has adhered to and tolerated her prescribed regimen.

Sources of information

Search strategy.

We searched MEDLINE, EMBASE, PubMed, Scopus, and the Cochrane Library for studies examining the effects of bariatric surgery on either drug absorption or chronic medication management. Search terms included obesity, obese, bariatric surgery, gastric bypass, gastrectomy, gastric band, RYGB, roux-en-y, gastrointestinal absorption, medication absorption, drug absorption, bioavailability, dose adjust, drug monitoring, medication adjust, drug change, medication change, medication management, and medication dosing. A librarian from the University of Alberta in Edmonton assisted with identification of appropriate search terms. Reference lists of original studies and reviews were also hand searched. Included studies were entered into PubMed and articles under the “Similar articles” heading were also reviewed. The search was limited to studies in human adults and is considered up to date as of February 2019.

Eligibility criteria.

Human case reports, case series, cohort studies, and randomized controlled trials that evaluated or described drug absorption or chronic medication management in patients undergoing bariatric surgery types currently available in Canada (ie, RYGB, sleeve gastrectomy, or gastric banding) were included. We excluded studies examining nutritional supplements such as vitamins and iron preparations.

Study selection.

Based on the inclusion and exclusion criteria, we independently screened the titles and abstracts of each study to determine eligibility. Both authors independently assessed all full-text articles that were classified as included or unclear for final inclusion. Disagreements were discussed and resolved by consensus.

Data abstraction.

Using standardized data extraction forms, we independently extracted data on study characteristics (eg, design, country, inclusion and exclusion criteria, funding sources), participants’ clinical characteristics, interventions (eg, medication name, dosage type, dosage amount, surgery type), level of agreement among the evidence, and outcomes. Data not reported in the articles were extracted from supplementary texts where available. Authors were not contacted for missing data.

Main message

General practice tips.

As physiologic and pharmacokinetic changes develop in the days to months after bariatric surgery, it is typically the responsibility of family physicians to modify chronic disease medication regimens in a timely and appropriate fashion. General strategies are available to manage medication regimens after bariatric surgery (Table 1).4–6 Strategies to improve medication absorption are not required for all patients; the decision to proactively implement these strategies will depend on many factors, including surgery type and each patient’s long-term medication regimen. In many cases it will be reasonable to monitor patients after surgery and make adjustments if suboptimal medication absorption is suspected.

View this table:
  • View inline
  • View popup
Table 1.

General approaches to medication management after bariatric surgery based on anticipated changes: Based on the anticipated medication and absorption changes after 3 specific procedures: 2 types of restrictive procedures (gastric banding and sleeve gastrectomy) and 1 type with both restrictive and malabsorptive properties (Roux-en-Y gastric bypass).

When reviewing general strategies for medication management after bariatric surgery, it is important to be mindful of these guiding principles:

  • Changes to absorption kinetics of drugs after bariatric surgery have high variability among individuals. No single algorithm or practice tool can accurately predict these changes for all patients after bariatric surgery.

  • Medication absorption issues might be temporary or permanent; therefore, medication modifications to counteract these issues might also be temporary or permanent.

  • Issues with medication absorption and dosage modifications are more likely to occur and persist after malabsorptive procedures.

  • When a medication adjustment is made, ensure appropriate monitoring and follow-up is implemented.

  • Ensure medication regimens that are dosed by weight are regularly reviewed and adjusted as patients experience weight loss.

Specific disease state management.

In addition to general management principles, we have identified a number of strategies to guide medication management for specific chronic disease states after bariatric surgery (Table 2).4–42 Specific medications for which recommendations are made are intended to represent the most commonly prescribed medications in Canada at the time of the literature review.

View this table:
  • View inline
  • View popup
Table 2.

Medication management strategies for specific chronic disease states after bariatric surgery: Based on the anticipated medication and absorption changes after 3 specific procedures: 2 types of restrictive procedures (gastric banding and sleeve gastrectomy) and 1 type with both restrictive and malabsorptive properties (RYGB).

Underlying pharmacokinetic changes.

After bariatric surgery, there are multiple pharmacokinetic changes that might occur and that might also explain why patients are not achieving an adequate response to their medications (Table 3).6,43–45 The resultant pharmacokinetic changes might develop within days to months after surgery, vary from patient to patient, and depend on the type of bariatric surgery performed. The changes might either partially or fully reverse as the body heals and adapts to the alterations made from bariatric surgery.

View this table:
  • View inline
  • View popup
Table 3.

Anticipated pharmacokinetic changes after bariatric surgery: Based on the anticipated medication and absorption changes after 3 specific procedures: 2 types of restrictive procedures (gastric banding and sleeve gastrectomy) and 1 type with both restrictive and malabsorptive properties (RYGB).

Case resolution

This patient’s hypertension has become poorly controlled after RYGB, most likely as a result of decreased absorption and efficacy of extended-release nifedipine. Extended-release oral nifedipine tablets use an osmotic gradient mechanism to control the release of medication; faster gastric transit time might result in incomplete emptying of tablets and thus incomplete absorption of medication. The family physician discontinues nifedipine and initiates 10 mg of oral amlodipine daily, while continuing ramipril as previously prescribed. Amlodipine and nifedipine have the same mechanism of action; however, amlodipine is available in a small immediate-release tablet and is less likely to be absorbed differently after bariatric surgery. The patient returns to the clinic 2 weeks later and presents with blood pressure at target, 136/84 mm Hg. In-clinic follow-up is planned for every 2 to 4 weeks until the patient’s weight loss stabilizes, and she is encouraged to monitor her blood pressure at home between appointments.

Conclusion

Owing to alterations in the gastrointestinal tract after bariatric surgery, there is an intuitive presumption that the absorption, and therefore effectiveness, of medications will change. This review describes changes to the absorption of medications that can be anticipated after bariatric surgery and provides clinical guidance for management of these changes. There is a paucity of previous high-quality literature to support medication management decisions after bariatric surgery. This review closes this gap and provides clinical guidance to practitioners by consolidating the best available evidence. Clinical guidance provided here must always be considered in conjunction with each patient’s clinical picture when adjusting medication regimens. To provide the best care to future bariatric surgery patients, further clinical studies are needed to reveal the effects of bariatric surgeries on drug absorption and to understand the underlying mechanisms. Awareness of this important issue must be stressed and it will be incumbent on prescribers to remain informed of new evidence in this area and adjust their practices accordingly.

Notes

Editor’s key points

  • ▸ There is a paucity of high-quality literature to support medication management decisions after bariatric surgery. This review describes changes to the absorption of medications that can be anticipated after bariatric surgery and provides clinical guidance for the management of these changes. Clinical guidance must always be considered in conjunction with each patient’s clinical picture when adjusting medication regimens.

  • ▸ General considerations include being aware of the high variability in absorption kinetics among patients; being aware that medication absorption issues might be temporary or permanent; knowing that issues with medication absorption and dosage modifications are more likely to occur and persist after malabsorptive procedures; and ensuring appropriate monitoring and follow-up is implemented.

  • ▸ This review provides practical tips on managing specific disease states and anticipating pharmacokinetic changes. Anticipated pharmacokinetic changes after bariatric surgery include reduced ability of solid oral medications to dissolve and altered first-pass metabolism. Suggestions for management include switching solid-medication doses to liquids, dissolvable or crushable tablets, or capsules that can be opened; nonoral dose forms; and immediate-release formulations.

Footnotes

  • Contributors

    Dr Lorico determined the initial search strategy, which was then modified after consultation with Mr Colton and a University of Alberta librarian. Dr Lorico identified all articles that met the search criteria. Dr Lorico and Mr Colton independently reviewed all titles and abstracts to determine which articles to include; discrepancies were resolved with discussion. Dr Lorico initially read the included articles and recorded pertinent results in a data collection spreadsheet; Mr Colton then read the articles to confirm the information and add to the data collection spreadsheet as required. Dr Lorico wrote most of the initial draft of the manuscript; Mr Colton proofread and edited it. All writing and editing was agreed upon by both authors. Consensus was achieved via discussion for all disputes.

  • Competing interests

    None declared

  • This article is eligible for Mainpro+ certified Self-Learning credits. To earn credits, go to www.cfp.ca and click on the Mainpro link.

  • This article has been peer reviewed.

  • La traduction en français de cet article se trouve à www.cfp.ca dans la table des matières du numéro de juin 2020 à la page e171.

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. Statistics Canada.
    Overweight and obesity based on measured body mass index, by age group and sex. Table 13-10-0373-01. Ottawa, ON: Statistics Canada; 2017. Available from: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310037301. Accessed 2019 Apr 26.
  2. 2.↵
    1. Guh DP,
    2. Zhang W,
    3. Bansback N,
    4. Amarsi Z,
    5. Birmingham CL,
    6. Anis AH
    . The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009;9:88.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Obesity Canada.
    Report card on access to obesity treatment for adults in Canada 2019. Edmonton, AB: Obesity Canada; 2019. Available from: http://obesitycanada.ca/wp-content/uploads/2019/04/OC-Report-Card-2019-Eng-F-web.pdf. Accessed 2019 Apr 26.
  4. 4.↵
    1. Miller AD,
    2. Smith KM
    . Medication and nutrient administration considerations after bariatric surgery. Am J Health Syst Pharm 2006;63(19):1852-7.
    OpenUrlAbstract/FREE Full Text
  5. 5.
    1. Brocks DR,
    2. Ben-Eltriki M,
    3. Gabr RQ,
    4. Padwal RS
    . The effects of gastric bypass surgery on drug absorption and pharmacokinetics. Expert Opin Drug Metab Toxicol 2012;8(12):1505-19. Epub 2012 Sep 24.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Azran C,
    2. Wolk O,
    3. Zur M,
    4. Fine-Shamir N,
    5. Shaked G,
    6. Czeiger D,
    7. et al
    . Oral drug therapy following bariatric surgery: an overview of fundamentals, literature and clinical recommendations. Obes Rev 2016;17(11):1050-66. Epub 2016 Jun 22.
    OpenUrl
  7. 7.
    1. Kheniser KG,
    2. Kashyap SR
    . Diabetes management before, during, and after bariatric and metabolic surgery. J Diabetes Complications 2018;32(9):870-5. Epub 2018 Jun 13.
    OpenUrl
  8. 8.
    1. Tritsch AM,
    2. Bland CM,
    3. Hatzigeorgiou C,
    4. Sweeney LB,
    5. Phillips M
    . A retrospective review of the medical management of hypertension and diabetes mellitus following sleeve gastrectomy. Obes Surg 2015;25(4):642-7.
    OpenUrlCrossRefPubMed
  9. 9.
    1. Bland CM,
    2. Tritsch AM,
    3. Bookstaver DA,
    4. Sweeney LB,
    5. Wiley D,
    6. Choi YU
    . Hypertension and diabetes mellitus medication management in sleeve gastrectomy patients. Am J Health Syst Pharm 2013;70(12):1018-20.
    OpenUrlFREE Full Text
  10. 10.
    1. Thorell A,
    2. Hagström-Toft E
    . Treatment of diabetes prior to and after bariatric surgery. J Diabetes Sci Technol 2012;6(5):1226-32.
    OpenUrlPubMed
  11. 11.
    1. Diabetes Canada Clinical Practice Guidelines Expert Committee.
    Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2018;42(Suppl 1):S1-325.
    OpenUrlCrossRefPubMed
  12. 12.
    1. Martin KA,
    2. Lee CR,
    3. Farrell TM,
    4. Moll S
    . Oral anticoagulant use after bariatric surgery: a literature review and clinical guidance. Am J Med 2017;130(5):517-24. Epub 2017 Feb 1.
    OpenUrl
  13. 13.
    1. Bechtel P,
    2. Boorse R,
    3. Rovito P,
    4. Harrison TD,
    5. Hong J
    . Warfarin users prone to coagulopathy in first 30 days after hospital discharge from gastric bypass. Obes Surg 2013;23(10):1515-9.
    OpenUrlCrossRefPubMed
  14. 14.
    1. Strong AT,
    2. Sharma G,
    3. Nor Hanipah Z,
    4. Tu C,
    5. Brethauer SA,
    6. Schauer PR,
    7. et al
    . Adjustments to warfarin dosing after gastric bypass and sleeve gastrectomy. Surg Obes Relat Dis 2018;14(5):700-6. Epub 2018 Jan 2.
    OpenUrl
  15. 15.
    1. Moore KT,
    2. Kröll D
    . Influences of obesity and bariatric surgery on the clinical and pharmacologic profile of rivaroxaban. Am J Med 2017;130(9):1024-32. Epub 2017 Jun 8.
    OpenUrl
  16. 16.
    1. Kushnir M,
    2. Gali R,
    3. Alexander M,
    4. Billett HHH
    . Efficacy and safety of direct oral factor Xa inhibitors in patients after bariatric surgery. Blood 2019;134(Suppl 1):2439.
    OpenUrl
  17. 17.
    1. Bays H,
    2. Kothari SN,
    3. Azagury DE,
    4. Morton JM,
    5. Nguyen NT,
    6. Jones PH,
    7. et al
    . Lipids and bariatric procedures part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA). Surg Obes Relat Dis 2016;12(3):468-95. Epub 2016 Jan 12.
    OpenUrl
  18. 18.
    1. Ties JS,
    2. Zlabek JA,
    3. Kallies KJ,
    4. Al-Hamadini M,
    5. Kothari SN
    . The effect of laparoscopic gastric bypass on dyslipidemia in severely obese patients: a 5-year follow-up analysis. Obes Surg 2014;24(4):549-53.
    OpenUrl
  19. 19.
    1. Saul D,
    2. Stephens D,
    3. de Cássia Hofstätter R,
    4. Ahmed L,
    5. Langhoff E,
    6. Heimann TM
    . Preliminary outcomes of laparoscopic sleeve gastrectomy in a Veterans Affairs medical center. Am J Surg 2012;204(5):e1-6. Epub 2012 Aug 14.
    OpenUrlCrossRefPubMed
  20. 20.
    1. Hinojosa MW,
    2. Varela JE,
    3. Smith BR,
    4. Che F,
    5. Nguyen NT
    . Resolution of systemic hypertension after laparoscopic gastric bypass. J Gastrointest Surg 2009;13(4):793-7. Epub 2008 Dec 3.
    OpenUrlCrossRefPubMed
  21. 21.
    1. Moloney BM,
    2. Hynes DA,
    3. Kelly ME,
    4. Iqbal A,
    5. O’Connor E,
    6. Lowe D,
    7. et al
    . The role of laparoscopic sleeve gastrectomy as a treatment for morbid obesity; review of outcomes. Ir J Med Sci 2017;186(1):143-9. Epub 2016 Jul 28.
    OpenUrl
  22. 22.
    1. Eisenberg D,
    2. Bellatorre A,
    3. Bellatorre N
    . Sleeve gastrectomy as a stand-alone bariatric operation for severe, morbid, and super obesity. JSLS 2013;17(1):63-7.
    OpenUrl
  23. 23.
    1. Roerig JL,
    2. Steffen K,
    3. Zimmerman C,
    4. Mitchell JE,
    5. Crosby RD,
    6. Cao L
    . Preliminary comparison of sertraline levels in postbariatric surgery patients versus matched nonsurgical cohort. Surg Obes Relat Dis 2012;8(1):62-6. Epub 2010 Dec 15.
    OpenUrlCrossRefPubMed
  24. 24.
    1. Hamad GG,
    2. Helsel JC,
    3. Perel JM,
    4. Kozak GM,
    5. McShea MC,
    6. Hughes C,
    7. et al
    . The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am J Psychiatry 2012;169(3):256-63.
    OpenUrlCrossRefPubMed
  25. 25.
    1. Krieger CA,
    2. Cunningham JL,
    3. Reid JM,
    4. Langman LJ,
    5. Grothe KB,
    6. Clark MM,
    7. et al
    . Comparison of bioavailability of single-dose extended-release venlafaxine capsules in obese patients before and after gastric bypass surgery. Pharmacotherapy 2017;37(11):1374-82. Epub 2017 Oct 10.
    OpenUrl
  26. 26.
    1. Roerig JL,
    2. Steffen KJ,
    3. Zimmerman C,
    4. Mitchell JE,
    5. Crosby RD,
    6. Cao L
    . A comparison of duloxetine plasma levels in postbariatric surgery patients versus matched nonsurgical control subjects. J Clin Psychopharmacol 2013;33(4):479-84.
    OpenUrlCrossRefPubMed
  27. 27.
    1. Lexi-Drugs [database online].
    Bupropion. Philadelphia, PA: Wolters Kluwer Health;
  28. 28.
    1. Gunay Y,
    2. Jamal M,
    3. Capper A,
    4. Eid A,
    5. Heitshusen D,
    6. Samuel I
    . Roux-en-Y gastric bypass achieves substantial resolution of migraine headache in the severely obese: 9-year experience in 81 patients. Surg Obes Relat Dis 2013;9(1):55-62. Epub 2012 Jan 21.
    OpenUrl
  29. 29.
    1. Bond DS,
    2. Vithiananthan S,
    3. Nash JM,
    4. Thomas JG,
    5. Wing RR
    . Improvement of migraine headaches in severely obese patients after bariatric surgery. Neurology 2011;76(13):1135-8.
    OpenUrlCrossRefPubMed
  30. 30.
    1. Sikka N,
    2. Wegienka G,
    3. Havstad S,
    4. Genaw J,
    5. Carlin AM,
    6. Zoratti E
    . Respiratory medication prescriptions before and after bariatric surgery. Ann Allergy Asthma Immunol 2010;104(4):326-30.
    OpenUrlPubMed
  31. 31.
    1. Van Huisstede A,
    2. Rudolphus A,
    3. Castro Cabezas M,
    4. Biter LU,
    5. van de Geijn GJ,
    6. Taube C,
    7. et al
    . Effect of bariatric surgery on asthma control, lung function and bronchial and systemic inflammation in morbidly obese subjects with asthma. Thorax 2015;70(7):659-67. Epub 2015 Apr 30.
    OpenUrlAbstract/FREE Full Text
  32. 32.
    1. Farias MM,
    2. Achurra P,
    3. Boza C,
    4. Vega A,
    5. de la Cruz C
    . Psoriasis following bariatric surgery: clinical evolution and impact on quality of life on 10 patients. Obes Surg 2012;22(6):877-80.
    OpenUrlCrossRefPubMed
  33. 33.
    1. Sako EY,
    2. Famenini S,
    3. Wu JJ
    . Bariatric surgery and psoriasis. J Am Acad Dermatol 2014;70(4):774-9. Epub 2014 Jan 7.
    OpenUrlCrossRefPubMed
  34. 34.
    1. Chan G,
    2. Hajjar R,
    3. Boutin L,
    4. Garneau PY,
    5. Pichette V,
    6. Lafrance JP,
    7. et al
    . Prospective study of the changes in pharmacokinetics of immunosuppressive medications after laparoscopic sleeve gastrectomy. Am J Transplant 2020;20(2):582-8.
    OpenUrl
  35. 35.
    1. Schulman AR,
    2. Chan WW,
    3. Devery A,
    4. Ryan MB,
    5. Thompson CC
    . Opened proton pump inhibitor capsules reduce time to healing compared with intact capsules for marginal ulceration following Roux-en-Y gastric bypass. Clin Gastroenterol Hepatol 2017;15(4):494-500. Epub 2016 Oct 20.
    OpenUrl
  36. 36.
    1. Amouyal C,
    2. Buyse M,
    3. Lucas-Martini L,
    4. Hirt D,
    5. Genser L,
    6. Torcivia A,
    7. et al
    . Sleeve gastrectomy in morbidly obese HIV patients: focus on anti-retroviral treatment absorption after surgery. Obes Surg 2018;28(9):2886-93.
    OpenUrlCrossRef
  37. 37.
    1. Fysekidis M,
    2. Cohen R,
    3. Bekheit M,
    4. Chebib J,
    5. Boussairi A,
    6. Bihan H,
    7. et al
    . Sleeve gastrectomy is a safe and efficient procedure in HIV patients with morbid obesity: a case series with results in weight loss, comorbidity evolution, CD4 count, and viral load. Obes Surg 2015;25(2):229-33.
    OpenUrl
  38. 38.
    1. MacBrayne C,
    2. Blum JD,
    3. Kiser JJ
    . Tenofovir, emtricitabine, and darunavir/ritonavir pharmacokinetics in an HIV-infected patient after Roux-en-Y gastric bypass surgery. Ann Pharmacother 2014;48(6):816-9. Epub 2014 Mar 10.
    OpenUrlCrossRefPubMed
  39. 39.
    1. Rocha ALL,
    2. Campos RR,
    3. Miranda MMS,
    4. Raspante LBP,
    5. Carneiro MM,
    6. Vieira CS,
    7. et al
    . Safety of hormonal contraception for obese women. Expert Opin Drug Saf 2017;16(12):1387-93. Epub 2017 Oct 11.
    OpenUrl
  40. 40.
    1. Curtis KM,
    2. Jamieson DJ,
    3. Petersen HB,
    4. Marchbanks PA
    . Adaptation of the World Health Organization’s Medical Eligibility Criteria for Contraceptive Use for use in the United States. Contraception 2010;82(1):3-9. Epub 2010 Mar 29.
    OpenUrl
  41. 41.
    Evra [product monograph]. Toronto, ON: Janssen Inc; 2018.
  42. 42.↵
    1. Westhoff CL,
    2. Torgal AH,
    3. Mayeda ER,
    4. Petrie K,
    5. Thomas T,
    6. Dragoman M,
    7. et al
    . Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women. Am J Obstet Gynecol 2012;207(1):39.e1-6. Epub 2012 Apr 28. Erratum in: Am J Obstet Gynecol 2013;208(4):326.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Padwal R,
    2. Brocks D,
    3. Sharma AM
    . A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev 2010;11(1):41-50. Epub 2009 Jun 2.
    OpenUrlCrossRefPubMed
  44. 44.
    1. Chan LN,
    2. Lin YS,
    3. Tay-Sontheimer JC,
    4. Trawick D,
    5. Oelschlager BK,
    6. Flum DR,
    7. et al
    . Proximal Roux-en-Y gastric bypass alters drug absorption pattern but not systemic exposure of CYP3A4 and P-glycoprotein substrates. Pharmacotherapy 2015;35(4):361-9. Epub 2015 Mar 10.
    OpenUrl
  45. 45.↵
    1. Brill MJ,
    2. van Rongen A,
    3. van Dongen EP,
    4. van Ramshorst B,
    5. Hazebroek EJ,
    6. Darwich AS,
    7. et al
    . The pharmacokinetics of the CYP3A substrate midazolam in morbidly obese patients before and one year after bariatric surgery. Pharm Res 2015;32(12):3927-36. Epub 2015 Jul 23.
    OpenUrl
PreviousNext
Back to top

In this issue

Canadian Family Physician: 66 (6)
Canadian Family Physician
Vol. 66, Issue 6
1 Jun 2020
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Medication management and pharmacokinetic changes after bariatric surgery
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Medication management and pharmacokinetic changes after bariatric surgery
Sabrina Lorico, Blaine Colton
Canadian Family Physician Jun 2020, 66 (6) 409-416;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Medication management and pharmacokinetic changes after bariatric surgery
Sabrina Lorico, Blaine Colton
Canadian Family Physician Jun 2020, 66 (6) 409-416;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Case description
    • Sources of information
    • Main message
    • Case resolution
    • Conclusion
    • Notes
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • Gestion des médicaments et changements pharmacocinétiques après la chirurgie bariatrique
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Practice

  • Is 45 the new 50 in colorectal cancer screening?
  • Approach to diagnosis and management of childhood attention deficit hyperactivity disorder
  • Determining if and how older patients can safely stay at home with additional services
Show more Practice

Clinical Review

  • Approach to nail trauma for primary care physicians
  • Approach to sialadenitis
  • Indications for omega-3 fatty acid supplementation in prevention of cardiovascular disease
Show more Clinical Review

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2023 by The College of Family Physicians of Canada

Powered by HighWire